KPV

Overview

KPV is a tripeptide composed of the amino acids lysine (K), proline (P), and valine (V), the C-terminal sequence (residues 11–13) of alpha-melanocyte-stimulating hormone (α-MSH). α-MSH is an endogenous tridecapeptide with well-documented anti-inflammatory properties, and a body of preclinical research has examined whether this short fragment retains anti-inflammatory activity on its own.

The published evidence for KPV is predominantly in vitro (cell culture) and in animal models, concentrated in two areas: intestinal inflammation (models of colitis) and dermal/keratinocyte inflammation. There are no well-established human clinical trials demonstrating efficacy or safety for any indication.

Naming

The compound is correctly named KPV, using the single-letter amino-acid codes for its sequence Lys-Pro-Val. It is also referred to as α-MSH(11–13) because it corresponds to the last three residues of α-MSH. The variant spelling "KVP" that sometimes appears is a letter transposition; it does not correspond to a distinct, separately validated peptide in the peer-reviewed literature. Throughout the scientific record (e.g., Dalmasso et al., 2008; Getting et al., 2003), the established designation is KPV.

Chemistry and structure

KPV is a small, three-residue peptide. Because it lacks the central "core" sequence of α-MSH required to bind melanocortin receptors, it is generally not expected to produce the pigmentary (melanocortin-receptor) effects of the full hormone. Researchers have used this point to argue that its anti-inflammatory activity is mechanistically distinct from classical melanocortin signaling.

Mechanism of action

The mechanisms below are derived from cell-culture and animal studies. They describe proposed and observed-in-model pathways, not established human pharmacology.

• NF-κB pathway inhibition. In intestinal epithelial and immune cell models, KPV at nanomolar concentrations reduced activation of the NF-κB and MAP kinase inflammatory signaling pathways, in part by limiting degradation of IκB-α, and lowered pro-inflammatory cytokine secretion (Dalmasso et al., 2008).
• PepT1-mediated cellular uptake. The same work reported that KPV is a substrate for the di/tripeptide transporter PepT1 (SLC15A1), which is expressed in the small intestine and can be induced in the inflamed colon. Uptake via PepT1 was associated with delivery of functional KPV into cells, where it exerted its anti-inflammatory effect (Dalmasso et al., 2008).
• Melanocortin-receptor-independent action. Comparative work found that the C-terminal KPV peptide produces an anti-inflammatory effect distinct from the core α-MSH peptides and is unlikely to act through melanocortin receptors, instead appearing to interfere with interleukin-1β (IL-1β)-driven functions (Getting et al., 2003).
• Oxidative-stress / MAPK–NF-κB modulation in skin cells. In keratinocytes, KPV was reported to reduce reactive oxygen species and modulate MAPK/NF-κB signaling under a particulate-matter inflammatory challenge (Sung et al., 2025).

Research and evidence

The table summarizes representative studies. All are in vitro or animal work; none are human clinical trials.

Human evidence. As of this entry's update, there are no well-established peer-reviewed human clinical trials establishing the efficacy or safety of KPV for inflammatory bowel disease, dermatologic conditions, or any other indication. Claims that KPV "treats" any disease in humans are not supported by controlled clinical data. The research remains preclinical, and findings in cells and rodents do not reliably translate to humans.

For context, KPV is sometimes discussed alongside other peptides studied in tissue-repair and inflammation contexts, such as BPC-157. As with KPV, much of that surrounding literature is also preclinical; readers should not infer human efficacy from animal data.

Status and regulation

KPV is best described as a research chemical. It is not an approved drug in the United States or other major jurisdictions, and it does not carry an approved indication, labeling, or standardized pharmaceutical classification.

In the context of U.S. pharmacy compounding, certain peptides — including KPV — have been the subject of FDA evaluation under the framework for bulk drug substances used in compounding under section 503A of the Federal Food, Drug, and Cosmetic Act. Substances under that interim review process have at various times been placed into evaluation categories; placement, removal, or scheduling for advisory-committee review is part of an ongoing regulatory process and does not constitute drug approval or an endorsement of use. Regulatory status can change; readers should consult current FDA sources for the latest position.

Safety

• Human safety data are limited to absent. Because there are no substantial human clinical trials, the human safety profile, tolerability, drug interactions, and long-term effects of KPV are not established.
• Preclinical findings do not equal human safety. Favorable results in cells or rodents do not demonstrate that KPV is safe in people.
• Product quality is a separate concern. Material sold for research is not subject to pharmaceutical-grade manufacturing controls; identity, purity, sterility, and content are not guaranteed.
• No specific human pharmacokinetic parameters (including half-life) have been reliably established.

Legal status

The legal status of KPV varies by country and is best characterized as that of an unapproved research substance rather than a licensed medicine. It is not an approved therapeutic product, and possession, sale, and use are governed by local laws on research chemicals, unapproved drugs, and pharmacy compounding. Because regulatory positions differ across jurisdictions and change over time, no claim of legality for human use should be inferred from this entry.

How it compares

Within the healing and anti-inflammatory space covered here, KPV is best understood next to:

• BPC-157 — studied more for angiogenesis and gut/tendon repair; KPV's proposed action is anti-inflammatory (NF-κB pathway) rather than pro-angiogenic.
• TB-500: a thymosin-β4-related fragment studied for cell migration and repair.

All three are research chemicals with predominantly in-vitro and animal evidence and no human clinical trials; none is approved for human use. KPV is distinguished mainly by its small size and anti-inflammatory framing, not by stronger evidence. See the Recovery & injury overview for context.

Common misconceptions

• "KPV is an approved anti-inflammatory medication." It is not. No regulatory agency has approved KPV as a drug, and there are no established human efficacy trials.
• "KPV works exactly like α-MSH." KPV is only the C-terminal fragment of α-MSH. Evidence suggests its anti-inflammatory action is mechanistically distinct and does not rely on melanocortin-receptor binding, so it is not expected to reproduce α-MSH's pigmentary effects.
• "Animal colitis results prove KPV cures gut disease in people." Reductions in colitis severity were observed in mice, often with specialized delivery systems (e.g., nanoparticles). These results are hypothesis-generating, not evidence of human benefit.
• "KVP is a different, stronger peptide." "KVP" is a letter transposition of KPV. It is not a distinct, separately validated compound in the scientific literature.
• "Topical/cosmetic use is clinically validated." Some skin-cell (keratinocyte) studies are preliminary in vitro work; they do not establish clinical efficacy or safety in human skin.

Community claims & recent evidence

These points address claims circulating in the peptide community — including popular video "masterclasses" — checked against the primary sources we could reach. A knowledgeable presenter is not peer review, so each statement below was treated as a claim to verify. Two honest caveats first: "verified" here means we located a matching primary paper, and "we couldn't source it" means only that — not that a claim is false. A great deal of relevant research is not indexed in the databases we searched (paywalled journals, regional and non-English literature, conference abstracts, clinical practitioner experience, and unpublished or proprietary data), so absence of a traceable citation reflects the limit of what we could reach, not proof against the claim.

Verified additions

• A second independent group reproduced KPV's anti-inflammatory effect in the gut: KPV reduced disease severity in two separate mouse colitis models (DSS-induced and CD45RB^hi T-cell transfer), and the benefit persisted in mice carrying a non-functional MC1 receptor — direct evidence that the effect does not require melanocortin-receptor signalling. [Animal] (Kannengiesser et al., Inflammatory Bowel Diseases 2008)
• The clearest central-nervous-system study we found is a traumatic-brain-injury model, not a neurodegenerative-disease trial: a single 1 mg/kg intraperitoneal dose of KPV given 30 minutes after controlled cortical impact modestly reduced secondary lesion volume (≈21 vs ≈28 mm³, p = 0.016) and apoptotic cell counts (p = 0.002) in mice. [Animal] (Schaible et al., PLoS ONE 2013)
• In the accessible data, KPV behaves as a hydrophilic rather than lipophilic peptide: across ex-vivo human skin, passive permeation was below the limit of detection, and measurable delivery required microneedle microporation combined with iontophoresis. [In vitro] (Pawar et al., Journal of Pharmaceutical Sciences 2017)

Claims we could not corroborate

• "KPV acts on the MC1R/MC3R melanocortin receptors, so you must cycle it (e.g. 4–6 weeks on, 2–4 weeks off) to avoid receptor desensitisation." The published mechanism we can trace points the other way: KPV's anti-inflammatory action appears to be melanocortin-receptor-independent — it works in MC1R-null mice (Kannengiesser et al., 2008), does not compete with α-MSH at those receptors (Getting et al., JPET 2003), and enters cells via the PepT1 transporter (Dalmasso et al., Gastroenterology 2008). On that evidence, a receptor-desensitisation argument borrowed from melanocortin agonists does not obviously map onto KPV's own described pathway.
• "Valine makes KPV hydrophobic enough to slip through biological barriers and lipophilic enough to cross the blood–brain barrier." The data we found describe a positively charged, hydrophilic tripeptide with negligible passive skin penetration (Pawar et al., 2017), and the one CNS study we located delivered it by injection rather than by free barrier crossing (Schaible et al., 2013). The lipophilicity premise is not supported by the accessible literature.
• "KPV upregulates IL-10 and flips macrophages from M1 to M2." The M1→M2 / IL-10 polarisation evidence we can locate points to the synthetic dimer (CKPV)₂, a different molecule — not the KPV tripeptide (Ji et al., PLoS ONE 2013). We found no primary source attributing that specific effect to the KPV tripeptide itself, though we cannot rule out work we could not access.
• Precise figures such as "68% lower IL-6," "71% better glucose uptake," "74% fewer microglial markers," "62% psoriasis reduction," "43% faster wound closure," or "68% lower Alzheimer's risk." We could not trace any of these specific numbers to an identifiable KPV primary paper, and several of the cited journal/year pairs did not resolve to a locatable KPV study in the sources we searched. That does not make the figures wrong, but until a source can be identified they should be treated as unsourced rather than established.
• "Unresolved inflammation is the single root cause of Alzheimer's, Parkinson's, MS, atherosclerosis, chronic kidney disease, diabetes and cancer, and KPV fixes all of them." We found no controlled human KPV trials for any of these conditions in the accessible literature; the disease-specific citations we could reach describe inflammation biology in general, not KPV. On what is currently locatable, the KPV evidence base remains preclinical and concentrated in gut and skin models — a statement about the published record we can access, not a claim that no such effect could exist.
• "KPV reverses atherosclerosis in human patients — a 203-patient metabolic-syndrome trial (Catania, Metabolism 2019) cut CRP 54%, a 120-patient study (Peschke 2017) restored endothelial tight junctions, foam cells fell 54%, and plaque MMP dropped 47%." We could not resolve any of these to a real KPV study, and several of the named author/journal pairings do not correspond to locatable records: the journal "Vascular Medicine Review" does not appear to exist, no KPV paper by "Peschke" is indexed, and Anna Catania's genuine KPV work is on antimicrobial/host-defense activity and the synthetic (CKPV)₂ dimer — not a cardiometabolic patient trial. No KPV study for atherosclerosis, endothelial function, or metabolic syndrome is registered on ClinicalTrials.gov (0 results). On the record we can reach, the KPV evidence base is preclinical — intestinal (Dalmasso et al., Gastroenterology 2008) and skin/keratinocyte models, plus a single mouse brain-injury study — with no human cardiovascular data of any kind. As always, not locating these citations is the limit of our reach, not proof the claims are false; but the specific human-efficacy percentages should be treated as unsourced, not established. (The separate cholesterol-versus-inflammation and statin argument the same video makes is outside this peptide's scope.) [human-trial claims not traceable]

Combinations and interactions

The peptide community and YouTubers (notably influencer stacking guides) discuss pairing KPV with other compounds. This section explains what the evidence does and does not show for those combinations — it is not a protocol, a recommendation, or dosing guidance.

KPV + TB-500

There is no controlled human data on this combination: no clinical trial has tested KPV together with TB-500 for any endpoint, and even vendor and stack-guide sources concede the claimed "synergy" rests on community experience and mechanistic reasoning rather than controlled human trials. The pairing is nonetheless discussed as a "gut and healing" combination, on the reasoning that KPV (Lys-Pro-Val, alpha-MSH residues 11-13) calms the inflammatory milieu while TB-500 (a synthetic fragment tied to thymosin beta-4's actin-binding region) drives cell migration and tissue remodeling. Neither compound has robust standalone human efficacy data either — KPV's anti-inflammatory activity (NF-kB inhibition, reduced TNF-alpha/IL-1beta/IL-6, PepT1-mediated uptake) is almost entirely in vitro and rodent work [In vitro][Animal], and the strongest thymosin beta-4 human evidence comes from full-length Tbeta4 as a topical eye-drop (RGN-259), a different molecule and route from the injected TB-500 fragment [Animal][Human — full-length, topical only]. Pharmacologically the two act on directionally opposite pathways (KPV dampens inflammation; TB-500 is pro-angiogenic and pro-cell-migration by design), so there is no shared receptor to produce a classic pharmacodynamic interaction — but that also means the assumed synergy is unproven, while the additive injection burden and unverified grey-market product add risk without proven benefit.

Safety context worth naming: thymosin beta-4 is over-expressed in several solid tumors (e.g. colorectal adenocarcinoma, NSCLC) and preclinically increases tumor-cell migration and microvessel density, creating a theoretical concern about promoting an occult or existing malignancy — endogenous upregulation is not identical to exogenous dosing and no human harm is proven, but the mechanism is real [In vitro][Animal][Hypothesis]. TB-500 / thymosin beta-4 is also on the WADA Prohibited List (S2, prohibited at all times), relevant for any tested athlete. Neither KPV nor TB-500 is an approved drug; both are sold as grey-market "research" peptides, so unregulated-source material carries real risk of misidentified peptide, incorrect quantity, and bacterial-endotoxin/contaminant load. Finally, combining a systemic anti-inflammatory (KPV suppresses NF-kB and pro-inflammatory cytokines) with a tissue-growth agent in people who may self-treat undiagnosed GI disease could plausibly mask inflammation while stimulating proliferation, delaying appropriate diagnosis [Hypothesis].

This is research context only — not medical advice and not a protocol.

Frequently asked questions

Is inflammation really the root cause of Alzheimer's, cancer and other chronic diseases — and can KPV fix it?

This is the central premise of the popular "inflammation is killing you" framing, and it overstates the science. Chronic inflammation is associated with many conditions, but it is not established as the single root cause of Alzheimer's, cancer, diabetes or the others, and no such sweeping claim is settled in the literature [Hypothesis]. Critically, there are no human clinical trials of KPV for any of these diseases; the disease-specific citations circulating online describe inflammation biology in general, not KPV, and the actual KPV evidence base is preclinical and concentrated in gut and skin models [Animal] [In vitro].

Does KPV cross the blood–brain barrier and help the brain?

The claim that valine makes KPV "lipophilic enough to cross the blood–brain barrier" is incorrect. KPV is a small, positively charged, hydrophilic tripeptide — in ex-vivo human skin its passive permeation was below the limit of detection [In vitro] (Pawar et al., 2017). The one genuine central-nervous-system study is a mouse traumatic-brain-injury model in which KPV was injected (1 mg/kg intraperitoneally), not shown to freely cross the barrier, and it modestly reduced lesion volume in that acute-injury setting only [Animal] (Schaible et al., 2013). There is no evidence it treats neurodegenerative disease in humans.

Do you need to "cycle" KPV to avoid receptor desensitization?

No — this advice borrows a mechanism that does not apply to KPV. The cycling argument assumes KPV acts on melanocortin receptors (MC1R/MC3R) that could desensitize, but KPV's anti-inflammatory effect is melanocortin-receptor-independent: it still works in MC1R-null mice [Animal] (Kannengiesser et al., 2008), does not compete with α-MSH at those receptors [Animal] (Getting et al., 2003), and enters cells via the PepT1 transporter [In vitro] (Dalmasso et al., 2008). Because there are no human trials, this page gives no dosing or scheduling guidance regardless.

Is KPV proven to treat ulcerative colitis or inflammatory bowel disease?

Only in animals, not in people. Two independent groups reported that KPV reduced colitis severity in mouse models (DSS-induced and T-cell-transfer), often using specialized oral nanoparticle delivery to get it to the gut [Animal] (Dalmasso et al., 2008; Xiao et al., 2017; Kannengiesser et al., 2008). These are hypothesis-generating results — there are no well-established human clinical trials showing KPV treats IBD, and rodent findings do not reliably translate to humans.

Does KPV upregulate IL-10 and switch macrophages from M1 to M2?

This popular mechanism is misattributed. The IL-10 and M1→M2 macrophage-polarization evidence points to the synthetic dimer (CKPV)₂, which is a different molecule, not the KPV tripeptide itself [Animal] (Ji et al., 2013). The tripeptide's better-supported action is inhibition of NF-κB/MAPK inflammatory signaling in cell and animal models — attributing the dimer's polarization effect to KPV is not supported.

Is KPV approved, and is it safe to use?

KPV is best described as an unapproved research chemical, not an approved medicine, and it carries no approved indication in the US or other major jurisdictions. Because there are essentially no substantial human clinical trials, its human safety profile, tolerability, interactions and long-term effects are not established, and favorable results in cells or rodents do not demonstrate safety in people [Animal] [In vitro]. This page is educational only and is not dosing, sourcing, or medical advice; anyone considering health decisions should consult a licensed clinician.